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Marked enhancement in myocardial function 
resulting from overexpression of a human 
/3-adrenergic receptor gene 
Transgenic mice with intense cardiac expression of a human /3-adrenergic receptor gene were 
engineered and shown to display marked improvements in baseline myocardial and left ventricular 
function. Heart/body weight ratios and histologic appearance were not found to be significantly 
altered, suggesting that receptor gene expression did not induce pathologic changes. Given the 
substantial reduction in /]-adrenergic receptor density and resultant reduction in inotropic 
responsiveness observed in chronic heart failure, these findings represent a novel approach for 
increasing myocardial function with important clinical implications. (J THORAC CARDIOVASC SURG 
1995;109:236-41) 
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The  primary physiologic mechanism for enhanc- 
ing myocardial performance during stress involves 
stimulation of myocardial /3-adrenergic receptors 
(/3-ARs) by endogenous catecholamines. Further- 
more, the main therapeutic approach for augment- 
ing myocardial function involves administration of 
synthetic agonists, which stimulate myocardial/3-ARs 
(e.g., dopamine and dobutamine). However, in a 
number of cardiac disease states that result in 
chronic congestive heart failure, myocardial /3-AR 
function is impaired and /31-AR density markedly 
reduced. 1 This impairment in the myocardial/3-AR 
system significantly reduces inotropic responsive- 
ness and may further limit the ability of the myocar- 
dium to compensate for the primary disease pro- 
cess. 1
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We 2 have previously described the ability to target 
expression of an exogenous /3-AR gene to the 
myocardium of transgenic mice. Coupling the de- 
oxyribonucleic acid (DNA) coding sequence of the 
human /32-AR gene to an a-myosin heavy chain 
promoter  sequence can achieve intense myocardi- 
urn-specific expression of  the exogenous/3-AR. 2' 3 In 
this report, enhancement of  myocardial function 
induced by this/3-AR gene expression is described 
in detail. In addition, morphologic and histologic 
characterization of the transgenic hearts is pre- 
sented. Finally in the context of the known reduc- 
tion in /3-AR number in chronic heart failure, 1 
potential therapeutic implications of this work are 
discussed. 
Methods 
DNA construct and generation of transgenic animals. 
The DNA construct used for generation of the transgenic 
mice consisted of the human ~32-AR coding sequence 
coupled to the a-myosin heavy chain promoter. 2'3 This 
DNA was microinjected into the pronuclei of fertilized 
single cell mouse embryos, and the embryos were reim- 
planted into the oviduct of an adult female mouse. 4 
Offspring were screened for the presence of the exoge- 
nous gene by Southern analysis of DNA extracted from 
tail cuts, and founder mice were identified. These 
founders were bred with normal mice to generate a line of 
transgenic mice; two lines of transgenic mice that contain 
the exogenous gene (TG4 and TG33) are described in this 
report. All animal manipulations were conducted after 
appropriate anesthesia in accordance with institutional 
review board and National Institutes of Health guidelines 
(NIH Publication No. 86-23, revised 1985). All data 
presented were obtained on either transgenic or control 
adult mice, approximately 2 months of age. 
Ligand binding assay. Excised hearts were placed in ice 
cold lysis buffer (Tris HC1, 5 mmol/L [pH 7.4], and 
EDTA,* 5 mmol/L) and homogenized. After an initial 500 
g centrifugation, the supernatant was removed and centri- 
fuged at 40,000 g and the resultant pelleted membrane 
fraction was resuspended in binding buffer (Tris HC1, 75 
mmol/L [pH 7.4], MgC12, 12.5 retool/L, and EDTA, 2 
mmol/L.) Saturation binding assays were then performed 
on the membrane fractions in the presence of [12sI]- 
cyanopindolol, 500 pmol/L (a/3-AR-specific ligand); non- 
specific binding was determined in the presence of alpre- 
nolol, 20/xmol/L. Reactions were conducted at 37 ° C for 
1 hour and then terminated by vacuum suction through 
glass fiber filters. Filters were counted in a gamma counter 
and receptor density was expressed as mean membrane 
protein (picomoles per milligram) plus or minus standard 
error of the mean. s 
Immunohistochemical l beling. Frozen sections were 
cut at 7 /xm for indirect immunofluorescence studies. 
Sections were rinsed three times for 3 minutes in phos- 
phate-buffered saline solution (PBS) and 3 minutes in 
*Ethylenediaminetetraacetic acid.
PBS with 0.05% Triton X-100 (Triton-PBS), blocked with 
serum diluent (10% goat serum in PBS with 0.1% bovine 
serum albumin and 0.1% sodium azide), and then rinsed 
for 15 minutes in Triton-PBS before overnight incubation 
at 4 ° C with a primary rabbit antihuman/32-AR antiser- 
um 6 (1:500 dilution in serum diluent). The sections were 
then washed four times for 10 minutes in Triton-PBS at 
room temperature and incubated for 1 hour in fluorescein 
isothiocyanate-conjugated goat antirabbit immunoglobu- 
lin G (1:50 dilution in serum diluent). After five 3-minute 
rinses in PBS, the sections were mounted with sodium 
iodide (25 gin/L) in 1:1 PBS/glycerol solution and photo- 
graphed. 
Isolated myocardial function. After excision of the 
heart, the atria were dissected and suspended at optimal 
resting tension in an organ bath in carbogenated modified 
Krebs bicarbonate solution (NaHCO3, 25 mmol/L [pH 
7.4]; NaC1, 118 retool/L; KC1, 4.8 retool/L; MgSO47H20, 
1.2 mmol/L; KH2PO4, 1.2 mmol/L; CaCle2HaO , 1.75 
mmol/L; glucose, 10 retool/L; NaSeOs, 0.1 retool/L; 
EDTA, 0.03 retool/L), supplemented with ascorbic acid 
(1.1 × 10 -4 mol/L), cocaine (1 × 10 -5 tool/L), cortico- 
sterone (4 × 10 -5 tool/L), and phentolamine (3 × 10 -6 
mol/L). Left atria were paced with a pulse duration of 3 
msec and the voltage set at threshold plus 20%; rates were 
not different between the two groups. Isometric developed 
tension was measured at baseline and after administration 
of isoproterenol, 3 × 10 -8 mol/L, the dose that effected a
maximum response. Data are given as the means plus or 
minus standard error of the mean. 
In vivo cardiac function. After anesthesia, a cervical 
incision was performed, the trachea intubated, and the 
animal connected to a volume-cycled ventilator. A carotid 
artery was then cannulated with a flame-stretched PE 50 
catheter connected to a modified P50 Statham transducer 
(Viggo Spectramed Inc., Critical Care Div., Oxnard, 
Calif.). The chest and pericardium were then opened and 
a 2F high-fidelity micromanometer catheter (Millar In- 
struments, Inc., Houston, Tex.) was inserted into the left 
atrium, advanced across the mitral valve, and secured in 
the left ventricle (LV). Continuous aortic pressures, LV 
systolic and diastolic pressures, and the derivative of LV 
pressure (LV dP/dt) were recorded on an eight-channel 
chart recorder and in digitized form on computer disk 
for beat averaging (codas, Dataq Instruments, Akron, 
Ohio). 7 Ten sequential beats were averaged for each 
measurement (CORDAT, Essen, Germany) and the 
data were expressed as the mean plus or minus standard 
deviation. In separate experiments, these parameters 
were recorded both at baseline and 4 minutes after the 
systemic administration of 5 /xg of ICI-118551, a/32-AR 
antagonist. 
Heart/body weight ratios and histologic evaluation. 
Wet heart/body weight ratios were determined as previ- 
ously described and expressed as the mean plus or minus 
standard deviation. 8 Hearts were then fixed in a 1% 
formaldehyde solution and processed for paraffin embed- 
ding. LV sagittal sections were then generated, labeled 
with wheat-germ agglutinin, and myocyte cross-sectional 
areas were determined. 8 
Atrial natriuretic factor (ANF) Northern blots. Ven- 
tricular ribonucleic acid (RNA) was extracted, fraction- 
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Fig. 1. Immunohistochemical labeling of the myocardium was performed on longitudinal ventricular 
sections with antisera specific for the human/32-AR: A, Control nontransgenic mouse. B, TG4 transgenic 
mouse. Inset displays the mean/3-AR densities for four control versus four TG4 hearts. 
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Fig. 2. Isometric developed tension was measured for 
control (n = 8), TG4 transgenic (n = 4), and TG33 
transgenic (n = 4) isolated left atria. All atria were paced 
at similar rates. The asterisks indicatep < 0.05, Student's 
t test, for the transgenic baseline or isoproterenol stimu- 
lated tension value relative to the respective control value. 
ated on a 1% agarose formaldehyde g l, and transferred 
to a nitrocellulose membrane as previously described. 8 
Nitrocellulose membranes were prehybridized and then 
hybridized with a random-primer radiolabeled ANF 
cDNA probeS; blots were stripped and reprobed with the 
rat glyceraldehyde 3-phosphate dehydrogenase cDNA 
probe (Ambion, Austin, Tex.). 
Results and discussion 
Immunohistochemistry performed on ventricular 
myocardial sections with an antiserum specific for 
the human/32-AR demonstrated impressive labeling 
of the transgenic myocardium with virtually no 
labeling of control tissue (Fig. 1)./3-AR density was 
quantitated by radioligand binding and was found to 
be increased approximately 175-fold in the TG4 
animals over control levels (Fig. 1, inset). This level 
of receptor overexpression results from the a-myo- 
sin heavy chain promoter, which is a strong myocar- 
dial promoter. 2' 3 
Measurement of isometric tension development is 
a specific test of myocardial function and eliminates 
potentially confounding differences resulting from 
alterations in preload or afterload. Isolated mouse 
atria provide a stable preparation for the quantita- 
tion of isometric tension development. Atria from 
two separate lines of transgenic mice (TG4 and 
TG33) were compared to control atria (Fig. 2), and 
markedly enhanced baseline tension (greater than 
threefold increase) was present in the transgenic 
animals relative to control animals. Isometric ten- 
sion after isoproterenol administration was also 
significantly greater in the transgenic myocardium 
relative to control values. The transgenic myocardial 
response to isoproterenol was minimal, suggesting 
that biochemical elements of contractility beyond 
the /3-AR system become limiting such as calcium 
channels or myosin adenosine triphosphatase activ- 
ity. 
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Fig. 3. A, Baseline LV dP/dtm~ , was determined for control mice (n = 7) and TG4 transgenic mice (n = 
7). The asterisks indicate p < 0.05, Student's t test, relative to control. B, In separate xperiments, LV 
dP/dtm~, was determined in TG4 transgenic mice (n = 5) at baseline and 4 minutes after the systemic 
administration f 5 tzg of ICI-118561 (a/3-AR antagonist). Asterisks indicatep < 0.05, paired Student's t 
test. 
The development ofmicrosurgical techniques has 
allowed for in vivo measurements of LV hemody- 
namics, 7 and baseline parameters were measured in 
TG4 transgenic mice and compared with control 
mice. Heart rates were significantly elevated in the 
transgenic mice relative to control mice (441 __+ 44 
versus 349 --- 21 beats/min, respectively; n = 7); 
mean aortic pressures and LV end-diastolic pres- 
sure, however, were not different. Under these 
conditions, LV maximal dP/dt (LV dP/dtmax) is an 
accurate parameter of LV performance, and in the 
transgenic animals, significant increases in LV dP/ 
dtma xwere present relative to control values (Fig. 3, 
A). 
To demonstrate hat the enhanced LV function 
resulting from the /3-AR overexpression could be 
regulated in vivo, we measured LV dP/dtma ~before 
and after the systemic administration of the/32-AR 
antagonist, ICI-118551. Marked decreases in the 
elevated baseline LV dP/dtmax were effected in all 
transgenic animals (Fig. 3, B); control animals dem- 
onstrated no significant change in response to the 
administration of this agent (data not shown). This 
study demonstrates that the functional enhance- 
ment in these transgenic animals can be readily 
Table I 
Control TG4 (/32-AR) 
Heart/body weight ratio 5.65 + 0.55 5.94 -+ 0.63 
(mg/gm) (n = 11) (n = 11) 
Ventricular myocyte 208 -4- 43 233 + 30 
cross-sectional rea (n = 5) (n = 5) 
(~m 2) 
Heart/body weight ratios and LV myocyte cross-sectional reas were 
compared between TG4 transgenic and control mice. For myocyte cross- 
sectional areas, five hearts were studied for each group and for each heart 
a mean cross-sectional area was determined from the measurement of 100 
LV free wall myocytes; the average of the 5 means -+ the standard 
deviation is shown for each group. For both parameters, no significant 
difference was detected between the transgcnic and the control values (p > 
0.05, Student's t test). 
modulated by the systemic administration of a spe- 
cific/3-AR antagonist; the molecular mechanisms by 
which this antagonist effects these changes probably 
involves more than the displacement of endogenous 
catecholamines from the overexpressed receptors. 9
Given the chronic, marked functional increases 
that were present in these transgenic mice, animals 
*Bond RA, Johnson TD, Milano CA, et al. Demonstrat ion of 
inverse agonists in transgenic mice overexpressing the /32- 
adrenoceptor. Unpubl ished ata. 
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Fig. 4. ANF Northern blot analysis. Each lane was loaded with 8 txg of ventricular total RNA and 
represents a different animal: control nontransgenic (n = 2), TG4 transgenic (n = 5), and mice with 
genetically induced ventricular hypertrophy (positive control, n = 2). The blot was probed first with an 
ANF cDNA probe and subsequently with a GAPDH cDNA probe to demonstrate equivalent RNA
loading. 
were evaluated for the development of cardiac 
disease. Heart/body weight ratios were minimally 
altered when a large group of transgenic animals 
were compared with controls (Table I). LV myocyte 
cross-sectional areas were not significantly increased 
in the transgenic hearts relative to controls, confirm- 
ing the absence of hypertrophy (Table I). Further- 
more, fibrosis or myocyte necrosis was not present in 
transgenic myocardial sections. Finally, ventricular 
ANF mRNA levels, a sensitive molecular marker 
associated with pressure-overload hypertrophy, l° 
were assessed by Northern blot analysis (Fig. 4). A 
very weak ANF signal was present on Northern blots 
of normal control ventricular mRNA and mRNA 
from five TG4 animals. Conversely, mRNA from 
animals with genetically induced ventricular hyper- 
trophy 8 characteristically had a very strong signal. 
Equivalent signals obtained with the glyceraldehyde 
3-phosphate dehydrogenase probe excluded un- 
equal mRNA loading or degradation. Together, 
these data suggest that the functional enhancement 
generated by/3-AR overexpression does not effect 
significant morphologic or histologic alteration. Fur- 
thermore, the normal myocyte gene expression ap- 
pears unaltered. 
In this report, overexpression of an exogenous 
/3-AR gene in the myocardium is presented as a 
novel means of enhancing myocardial and ventricu- 
lar function. Deleterious histologic or morphologic 
changes did not appear to be associated with this 
augmented function. Furthermore, these functional 
increases could be regulated by the systemic admin- 
istration of a specific /32-AR antagonist.* More 
generally, this report highlights the utility of trans- 
genic animals generated with myocardium-specific 
promoters for studying the effects of altered gene 
expression on myocardial function. 
Recent studies have demonstrated the ability of 
recombinant, replication-deficient adenovirus to 
transfer genes to the myocardium of adult experi- 
mental animals and effect significant levels of ex- 
pression, al Such an approach may be useful for 
myocardial /3-AR gene transfer and may achieve 
increased levels of receptor expression capable of 
enhancing cardiac function. Furthermore, given the 
specific defects in the/3-AR system in patients with 
chronic congestive heart failure, therapeutic efforts 
to transfer/3-AR genes to the myocardium in vivo 
represent a promising area for future clinical inter- 
vention. 
*Bond RA, Johnson TD, Milano CA, et al. Demonstration of
inverse agonists in transgenic mice overexpressing the /3 2- 
adrenoceptor. Unpublished ata. 
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Discussion 
Dr. Stanley K. C. Tam (Boston, Mass.). In heart failure 
/3-adrenergic receptors are down-regulated, presumably 
to protect he myocardium from elevated levels of adren- 
ergic stimuli. What do you think overexpression of this 
same receptor in a failing heart will do? 
Is c~-myosin heavy chain up-regulated or down-regu- 
lated in heart failure as opposed to 13-myosin heavy chain? 
Dr. Milano. Reports have not demonstrated that down- 
regulation of/3-adrenergic receptors represents a protec- 
tive effect, and we believe that this down-regulation may 
inhibit the ability of the myocardium to compensate for 
the primary disease that is causing the impairment of 
myocardial function. 
The c~-myosin heavy chain may be down-regulated in 
heart failure, but this is a species-dependent process. 
However, other promoter sequences could be used to 
overexpress the/3-adrenergic receptor. 
Mr. Thoralf M. Sundt (Harefield, England). Two bands 
appeared to be expressed on your Northern blot. Is that 
correct, or was I misreading your blot? 
Dr. Milano. There is one predominant band of the 
appropriate size, which is roughly 2.4 kb. I think the lower 
labeling represents some degradation of the RNA on that 
blot. 
Dr. Andrew S. Wechsler (Richmond, Va.). I was sur- 
prised that in the isolated atria there appeared to be 
enhanced intrinsic contractile function, which almost 
looked greater than the increment hat you got with a 
/3-adrenergic agonist. Were you surprised by that or can 
you explain that? 
Dr. Milano. Initially we thought we would find a greater 
response to isoproterenol rather than an increase in 
baseline function. However, what seems to be happening 
is that when the receptor is so greatly overexpressed, the 
percentage of the receptor that remains in the activated 
state even in the absence of agonist (for example, isopro- 
terenol or catecholamine in the sense of the in vivo 
setting) becomes ignificant. Since there is such a large 
pool of receptors in these transgenic animals, the small 
fraction that remains activated becomes ignificant and 
results in a completely activated system in the absence of 
agonists. 
